Galectin Therapeutics Inc GALT:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
2.18quote price arrow down-0.15 (-6.44%)
Volume
353,896
52 week range
1.50 - 3.85

...

Loading . . .

KEY STATS

  • Open2.26
  • Day High2.28
  • Day Low2.08
  • Prev Close2.33
  • 52 Week High3.85
  • 52 Week High Date09/28/20
  • 52 Week Low1.50
  • 52 Week Low Date03/19/20
  • Market Cap124.43M
  • Shares Out57.08M
  • 10 Day Average Volume0.29M
  • Dividend-
  • Dividend Yield-
  • Beta2.04
  • 1 Year % Change-11.38

RATIOS/PROFITABILITY

  • EPS (TTM)-0.40
  • P/E (TTM)-5.52
  • Fwd P/E (NTM)-3.30
  • EBITDA (MRQ)-20.80M
  • ROE (MRQ)-54.60%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/15/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Galectin Therapeutics Inc News

There is no recent news for this security.

Latest GALT News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular...
Richard Uihlein
Non-Executive Chairman
Joel Lewis CPA
President
Jack Callicutt CPA
Chief Financial Officer
Eliezer Zomer Ph.D.
Executive Vice President
Address
4960 Peachtree Industrial Blvd Ste 240
Berkeley Lake, GA
30071-1580
United States